Access all of the content
It was a great pleasure to meet with Prof. Paul Heath (St George’s, University of London, London, UK) to discuss the findings from the Phase III Novavax clinical trial that is investigating the safety and efficacy of NVX-CoV2373, a vaccine candidate for COVID-19. Please find Part 2 of this interview available here.
To access more COVID-19 content, please visit our COVID-19 Hub.
- What is the design of the Novavax vaccine, and how is it stored and administered? (0:25)
- Could you give us a brief overview of the Phase III Novavax clinical trial? (2:03)
- What were the safety findings of the study? (8:02)
- What questions remain unanswered about the vaccine efficacy and safety? (10:19)
Disclosures: Paul Heath has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In COVID-19
Ruth Link-Gelles, IDWeek 2022: Efficacy of COVID-19 vaccination in paediatric populations
In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss the incidence of COVID-19 in children, vaccine effectiveness against infection and disease severity, and the current status of paediatric COVID-19 vaccines in the United States. Interviews available in this series: Real world […]
Ruth Link-Gelles, IDWeek 2022: Real world effectiveness of paediatric COVID-19 vaccination
COVID-19 typically causes less severe illness and fewer deaths in children and adolescents compared to adults. Nonetheless, children and adolescents remain susceptible to COVID-19 infection and can transmit to others. In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss real-world findings of […]
Christoph Boesecke: Impact of COVID-19 on the treatment of patients living with HIV
Key clinical highlights in HIV infection are discussed in this interview with touchINFECTIOUS DISEASES Editorial Board member, Dr Christoph Boesecke (Infectious Diseases Specialist, Senior Lecturer, University of Bonn, Bonn, Germany). He discusses the delays caused by the COVID-19 pandemic and the impact that has had on the treatment of patients living with HIV. He also […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!